Clinical benefit of radiation therapy and metallic stenting for unresectable hilar cholangiocarcinoma

doi:10.3748/wjg.v18.i19.2364

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 18, Issue 19

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (4326)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-4) series, Tables (1-3) series.

Item

Count

PDF

409

HTML

3501

Figures (1-4)

211

Tables (1-3)

205

Sum=4326

May 21, 2012 (publication date) through Nov 26, 2024

Times Cited of This Article

Times Cited (30)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Brief Article

World J Gastroenterol. May 21, 2012; 18(19): 2364-2370
Published online May 21, 2012. doi: 10.3748/wjg.v18.i19.2364

Table 2 Details of biliary drainage and anti-cancer therapy

	Patient group
	Radiotherapy	BSC	Pvalue
Cases	28	11
Biliary metallic stenting	24	10
Drainage area			0.0630
Bilateral	14	2
Unilateral	10	8
Insertion route			0.0339
Endoscopic	4	6
Percutaneous	20	4
PTBD only	3	1	> 0.9999
No need for drainage	1	0	> 0.9999
Anti-cancer therapy
Radiotherapy	28	-
Extra corporeal (50 Gy)	28	-
Intra bile duct (24 Gy)	11	-
Additional chemotherapy	16	-
Gemcitabine	1	-
S-1	6	-
5FU-based regimen	9	-

Three patients in the radiotherapy group and one in the BSC group did not receive a metallic stent but underwent PTBD alone; cholangitis occurred after endoscopic stenting, and patients were treated with PTBD. A total of 16 patients were administered additional systemic chemotherapy, with 9 receiving a 5-fluorouracil (5FU)-based regimen, 6 receiving S-1, and 1 receiving gemcitabine. PTBD: Percutaneous transhepatic biliary drainage; BSC: Best supportive care.

Citation: Isayama H, Tsujino T, Nakai Y, Sasaki T, Nakagawa K, Yamashita H, Aoki T, Koike K. Clinical benefit of radiation therapy and metallic stenting for unresectable hilar cholangiocarcinoma. World J Gastroenterol 2012; 18(19): 2364-2370
URL: https://www.wjgnet.com/1007-9327/full/v18/i19/2364.htm
DOI: https://dx.doi.org/10.3748/wjg.v18.i19.2364